RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 111 filers reported holding RHYTHM PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,237,249 | +0.7% | 2,365,856 | -27.6% | 0.00% | 0.0% |
| Q2 2023 | $53,879,838 | +15.6% | 3,267,425 | +25.1% | 0.00% | 0.0% |
| Q1 2023 | $46,601,434 | -74.8% | 2,612,188 | -58.9% | 0.00% | -40.0% |
| Q4 2022 | $185,243,852 | +141.7% | 6,361,396 | +103.4% | 0.01% | 0.0% |
| Q3 2022 | $76,634,000 | +7254.5% | 3,127,905 | +1145.9% | 0.01% | – |
| Q2 2022 | $1,042,000 | -88.8% | 251,059 | -69.1% | 0.00% | – |
| Q1 2022 | $9,345,000 | -51.5% | 811,183 | -58.0% | 0.00% | -100.0% |
| Q4 2021 | $19,272,000 | -33.7% | 1,931,090 | -13.2% | 0.00% | -50.0% |
| Q3 2021 | $29,055,000 | -31.9% | 2,224,717 | +2.1% | 0.00% | 0.0% |
| Q2 2021 | $42,667,000 | -17.8% | 2,179,087 | -10.7% | 0.00% | -33.3% |
| Q1 2021 | $51,928,000 | +36.6% | 2,441,380 | +90.9% | 0.00% | +50.0% |
| Q4 2020 | $38,028,000 | +98.5% | 1,279,119 | +44.7% | 0.00% | +100.0% |
| Q3 2020 | $19,156,000 | -24.4% | 883,980 | -22.2% | 0.00% | -50.0% |
| Q2 2020 | $25,344,000 | +70.3% | 1,136,492 | +16.2% | 0.00% | +100.0% |
| Q1 2020 | $14,881,000 | -30.5% | 977,701 | +4.8% | 0.00% | 0.0% |
| Q4 2019 | $21,411,000 | +38.2% | 932,520 | +30.0% | 0.00% | 0.0% |
| Q3 2019 | $15,492,000 | +16.5% | 717,540 | +18.7% | 0.00% | 0.0% |
| Q2 2019 | $13,296,000 | +2.7% | 604,376 | +27.9% | 0.00% | 0.0% |
| Q1 2019 | $12,948,000 | -0.7% | 472,386 | -2.6% | 0.00% | 0.0% |
| Q4 2018 | $13,037,000 | -34.7% | 485,023 | -29.1% | 0.00% | -50.0% |
| Q3 2018 | $19,954,000 | +214.5% | 684,072 | +237.2% | 0.00% | +100.0% |
| Q2 2018 | $6,344,000 | +177.2% | 202,885 | +76.5% | 0.00% | – |
| Q1 2018 | $2,289,000 | -19.1% | 114,954 | +18.2% | 0.00% | – |
| Q4 2017 | $2,828,000 | – | 97,294 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |